Results overview: Found 11 records in 0.05 seconds.
Articles, 10 records found
Research literature, 1 records found
Articles 10 records found  
1.
17 p, 1.3 MB Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics / Tijms, Betty M (Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam) ; Gobom, Johan (Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg) ; Reus, Lianne (Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam) ; Jansen, Iris (Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam) ; Hong, Shengjun (Lübeck Interdisciplinary Platform for Genome Analytics (LIGA), Institutes of Neurogenetics and Cardiogenetics, University of Lübeck) ; Dobricic, Valerija (Lübeck Interdisciplinary Platform for Genome Analytics (LIGA), Institutes of Neurogenetics and Cardiogenetics, University of Lübeck) ; Kilpert, Fabian (Lübeck Interdisciplinary Platform for Genome Analytics (LIGA), Institutes of Neurogenetics and Cardiogenetics, University of Lübeck) ; ten Kate, Mara (Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam) ; Barkhof, Frederik (Institutes of Neurology and Healthcare Engineering, UCL London) ; Tsolaki, Magda (1st Department of Neurology, AHEPA University Hospital, Makedonia) ; Verhey, Frans R J (Alzheimer Center Limburg, School for Mental Health and Neuroscience, Maastricht University) ; Popp, Julius (Geriatric Psychiatry, Department of Psychiatry, Geneva University Hospital) ; Martinez-Lage, Pablo (Fundación CITA-Alzhéimer Fundazioa) ; Vandenberghe, Rik (Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven) ; Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ; Molinuevo, José Luís (Alzheimer's Disease Unit and Other Cognitive Disorders Unit, Hospital Clinic de Barcelona) ; Engelborghs, Sebastiaan (Department of Neurology, UZ Brussel and Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB)) ; Bertram, Lars (Lübeck Interdisciplinary Platform for Genome Analytics (LIGA), Institutes of Neurogenetics and Cardiogenetics, University of Lübeck) ; Lovestone, Simon (Janssen R&D) ; Streffer, Johannes (UCB Biopharma SPRL) ; Vos, Stephanie (Alzheimer Center Limburg, School for Mental Health and Neuroscience, Maastricht University) ; Bos, Isabelle (Alzheimer Center Limburg, School for Mental Health and Neuroscience, Maastricht University) ; Blennow, Kaj (Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg) ; Scheltens, Philip (Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam) ; Teunissen, Charlotte E (Neurochemistry laboratory, Department of Clinical Chemistry, Amsterdam UMC - location VUmc, Amsterdam Neuroscience) ; Zetterberg, Henrik (UK Dementia Research Institute at UCL) ; Visser, Pieter Jelle (Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet) ; Universitat Autònoma de Barcelona
Using CSF proteomics, Tijms et al. identify three Alzheimer's disease subtypes that show: 1) hyperplasticity and increased BACE1 levels; 2) innate immune activation; and 3) blood-brain barrier dysfunction with low BACE1 levels. [...]
2020 - 10.1093/brain/awaa325
Brain, Vol. 143 (november 2020) , p. 3776-3792  
2.
9 p, 2.2 MB Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly / Pegueroles, Jordi (Institut d'Investigació Biomèdica Sant Pau) ; Pané, Adriana (Hospital Clínic i Provincial de Barcelona) ; Vilaplana, Eduard (Institut d'Investigació Biomèdica Sant Pau) ; Montal, Víctor (Institut d'Investigació Biomèdica Sant Pau) ; Bejanin, Alexandre (Institut d'Investigació Biomèdica Sant Pau) ; Videla, Laura (Institut d'Investigació Biomèdica Sant Pau) ; Carmona Iragui, María (Institut d'Investigació Biomèdica Sant Pau) ; Barroeta, Isabel (Institut d'Investigació Biomèdica Sant Pau) ; Ibarzabal, Ainitze (Hospital Clínic i Provincial de Barcelona) ; Casajoana, Anna (Hospital Universitari de Bellvitge) ; Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ; Valldeneu, Silvia (Institut d'Investigació Biomèdica Sant Pau) ; Altuna, Miren (Institut d'Investigació Biomèdica Sant Pau) ; de Hollanda, Ana (IDIBAPS) ; Vidal, Josep (IDIBAPS) ; Ortega, Emilio (IDIBAPS) ; Osorio, Ricardo (New York University School of Medicine) ; Convit, Antonio (New York University School of Medicine) ; Blesa, Rafael (Institut d'Investigació Biomèdica Sant Pau) ; Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ; Fortea, Juan (Institut d'Investigació Biomèdica Sant Pau) ; Jiménez, Amanda (IDIBAPS) ; Universitat Autònoma de Barcelona
Midlife obesity is a risk factor for dementia. We investigated the impact of obesity on brain structure, metabolism, and cerebrospinal fluid (CSF) core Alzheimer's disease (AD) biomarkers in healthy elderly. [...]
2020 - 10.1002/dad2.12052
Alzheimer's & dementia, Vol. 12 (july 2020)  
3.
9 p, 632.8 KB Human Albumin Impairs Amyloid β-peptide Fibrillation Through its C-terminus : From docking Modeling to Protection Against Neurotoxicity in Alzheimer's disease / Picón-Pagès, P. (Universitat Pompeu Fabra. Laboratori de Fisiologia Molecular) ; Bonet, J. (Universitat Pompeu Fabra. Grup de Recerca en Bioinformàtica Estructural) ; García-García, J. (Universitat Pompeu Fabra. Grup de Recerca en Bioinformàtica Estructural) ; Garcia-Buendia, J. (Universitat Pompeu Fabra. Laboratori de Fisiologia Molecular) ; Gutiérrez, Daniela (Pontificia Universidad Católica de Chile. Departamento de Biología Celular y Molecular) ; Valle, J. (Universitat Pompeu Fabra. Laboratory of Proteomics and Protein Chemistry) ; Gómez-Casuso, C.E.S. (Universitat Pompeu Fabra. Laboratori de Fisiologia Molecular) ; Sidelkivska, V. (Universitat Pompeu Fabra. Laboratori de Fisiologia Molecular) ; Alvarez, A. (Pontificia Universidad Católica de Chile. Departamento de Biología Celular y Molecular) ; Peralvarez-Marin, Alex (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular) ; Suades, A. (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular) ; Fernàndez-Busquets, X. (Barcelona Institute for Global Health (ISGlobal)) ; Andreu, D. (Universitat Pompeu Fabra. Laboratory of Proteomics and Protein Chemistry) ; Vicente, R. (Universitat Pompeu Fabra. Laboratori de Fisiologia Molecular) ; Oliva, B. (Universitat Pompeu Fabra. Grup de Recerca en Bioinformàtica Estructural) ; Muñoz, F.J. (Universitat Pompeu Fabra. Laboratori de Fisiologia Molecular)
Alzheimer's disease (AD) is a neurodegenerative process characterized by the accumulation of extracellular deposits of amyloid β-peptide (Aβ), which induces neuronal death. Monomeric Aβ is not toxic but tends to aggregate into β-sheets that are neurotoxic. [...]
2019 - 10.1016/j.csbj.2019.06.017
Computational and Structural Biotechnology Journal, Vol. 17 (2019) , p. 963-971  
4.
13 p, 787.1 KB Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease / Dekker, Alain D. (Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Wilrijk, Antwerp, Belgium) ; Vermeiren, Yannick (Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Wilrijk, Antwerp, Belgium) ; Carmona-Iragui, Maria (Down Medical Center, Catalan Down Syndrome Foundation, Barcelona, Spain) ; Benejam, Bessy (Down Medical Center, Catalan Down Syndrome Foundation, Barcelona, Spain) ; Videla, Laura (Down Medical Center, Catalan Down Syndrome Foundation, Barcelona, Spain) ; Gelpi, Ellen (Neurological Tissue Bank-Biobanc, Hospital Clinic Barcelona, Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain) ; Aerts, Tony (Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Wilrijk, Antwerp, Belgium) ; Van Dam, Debby (Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Wilrijk, Antwerp, Belgium) ; Fernández, Susana (Down Medical Center, Catalan Down Syndrome Foundation, Barcelona, Spain) ; Lleó Bisa, Alberto (Institut d'Investigació Biomèdica Sant Pau) ; Videla, Sebastian (Universitat Pompeu Fabra. Departament de Ciències Experimentals i de la Salut) ; Sieben, Anne (Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Wilrijk, Antwerp, Belgium) ; Martin, Jean-Jacques (Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Wilrijk, Antwerp, Belgium) ; Blesa, Rafael (Institut d'Investigació Biomèdica Sant Pau) ; Fortea, Juan (Down Medical Center, Catalan Down Syndrome Foundation, Barcelona, Spain) ; De Deyn, Peter P. (Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium) ; Universitat Autònoma de Barcelona
People with Down syndrome (DS) are at high risk for Alzheimer's disease (AD). Defects in monoamine neurotransmitter systems are implicated in DS and AD but have not been comprehensively studied in DS. [...]
2017 - 10.1016/j.dadm.2017.11.001
Alzheimer's & dementia, Vol. 10 (november 2017) , p. 99-111  
5.
8 p, 444.3 KB White paper by the Society for CSF Analysis and Clinical Neurochemistry : Overcoming barriers in biomarker development and clinical translation / Teunissen, Charlotte E. (Amsterdam, The Netherlands) ; Otto, Markus (Ulm, Germany) ; Engelborghs, Sebastiaan (Antwerp, Belgium) ; Herukka, Sanna-Kaisa (Kuopio, Finland) ; Lehmann, Sylvain (Université de Montpellier, University Hospital, INSERM U1183, Montpellier, France) ; Lewczuk, Piotr (Białystok, Poland) ; Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ; Perret-Liaudet, Armand (Lyon, France) ; Tumani, Hayrettin (Schwendi, Germany) ; Turner, Martin R. (Oxford, UK) ; Verbeek, Marcel M. (Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Departments of Neurology and Laboratory Medicine, Radboud Alzheimer Centre, Nijmegen, The Netherlands) ; Wiltfang, Jens (Aveiro, Portugal) ; Zetterberg, Henrik (UK Dementia Research Institute at UCL, London, UK) ; Parnetti, Lucilla (Perugia, Italy) ; Blennow, Kaj (Mölndal, Sweden) ; Universitat Autònoma de Barcelona
Body fluid biomarkers have great potential for different clinical purposes, including diagnosis, prognosis, patient stratification and treatment effect monitoring. This is exemplified by current use of several excellent biomarkers, such as the Alzheimer's disease cerebrospinal fluid (CSF) biomarkers, anti-neuromyelitis optica antibodies and blood neurofilament light. [...]
2018 - 10.1186/s13195-018-0359-x
Alzheimer's research & therapy, Vol. 10 (march 2018)  
6.
11 p, 1.6 MB Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease / Jimenez, Amanda (Institut d'Investigacions Biomèdiques August Pi Sunyer, Barcelona, Spain) ; Pegueroles, Jordi (Institut d'Investigació Biomèdica Sant Pau) ; Carmona Iragui, María (Institut d'Investigació Biomèdica Sant Pau) ; Vilaplana, Eduard (Institut d'Investigació Biomèdica Sant Pau) ; Montal, Victor (Institut d'Investigació Biomèdica Sant Pau) ; Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ; Videla, Laura (Institut d'Investigació Biomèdica Sant Pau) ; Illán-Gala, Ignacio (Institut d'Investigació Biomèdica Sant Pau) ; Pané, Adriana (Endocrinology and Diabetes Department, Obesity Unit, Hospital Clinic de Barcelona, Barcelona, Spain) ; Casajoana, Anna (General Surgery Service, Hospital de Barcelona-SCIAS, Barcelona, Spain) ; Belbin, Olivia (Institut d'Investigació Biomèdica Sant Pau) ; Clarimón, Jordi (Institut d'Investigació Biomèdica Sant Pau) ; Moizé, Violeta (Institut d'Investigacions Biomèdiques August Pi Sunyer, Barcelona, Spain) ; Vidal, Josep (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas) ; Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ; Fortea, Juan (Institut d'Investigació Biomèdica Sant Pau) ; Blesa, Rafael (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
Weight loss has been proposed as a sign of pre-clinical Alzheimer Disease (AD). To test this hypothesis, we have evaluated the association between longitudinal changes in weight trajectories, cognitive performance, AD biomarker profiles and brain structure in 363 healthy controls from the Alzheimer's Disease Neuroimaging Initiative (mean follow-up 50. [...]
2017 - 10.18632/oncotarget.22218
Oncotarget, Vol. 8 (october 2017) , p. 104706-104716  
7.
16 p, 688.9 KB Consensus guidelines for lumbar puncture in patients with neurological diseases / Engelborghs, Sebastiaan (Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium) ; Niemantsverdriet, Ellis (Reference Center for Biological Markers of Dementia (BIODEM), Department of Biomedical Sciences, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium) ; Struyfs, Hanne (Reference Center for Biological Markers of Dementia (BIODEM), Department of Biomedical Sciences, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium) ; Blennow, Kaj (Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden) ; Brouns, Raf (Department of Neurology, Universitair Ziekenhuis Brussel (UZ Brussel), Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Brussels, Belgium) ; Comabella, Manuel (Hospital Universitari Vall d'Hebron) ; Dujmovic, Irena (Clinic of Neurology, Clinical Centre of Serbia, Department of Neurology, Faculty of Medicine, University of Belgrade School of Medicine, Belgrade, Serbia) ; van der Flier, Wiesje (Alzheimer center and Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands) ; Frölich, Lutz (Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty, Mannheim/Heidelberg University, Mannheim, Germany) ; Galimberti, Daniela (Neurology Unit, Department of Pathophysiology and Transplantation, University of Milan, Fondazione Ca' Granda, IRCCS Ospedale Policlinico, Milan, Italy) ; Gnanapavan, Sharmilee (Department of Neuroscience and Trauma, Blizard Institute, Queen Mary University of London, London, United Kingdom) ; Hemmer, Bernhard (Munich Cluster for Systems Neurology (SyNergy), Munich, Germany) ; Hoff, Erik (Department of Neurology, Atrium Medisch Centrum Parkstad, Heerlen, The Netherlands) ; Hort, Jakub (International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic) ; Iacobaeus, Ellen (Department of Clinical Neuroscience, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden) ; Ingelsson, Martin (Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden) ; Jan de Jong, Frank (Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands) ; Jonsson, Michael (Memory Clinic, Department of Neuropsychiatry, Sahlgrenska University Hospital, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden) ; Khalil, Michael (Department of Neurology, Medical University Graz, Graz, Austria) ; Kuhle, Jens (Department of Neurology, University Hospital Basel, Basel, Switzerland) ; Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ; de Mendonça, Alexandre (Laboratory of Neurosciences, Department of Molecular Medicine and Faculty of Medicine, University of Lisbon, Lisbon, Portugal) ; Molinuevo, José Luis (Alzheimer's disease and other cognitive disorders unit, Neurology Service, Hospital Clinic i Universitari, IDIBAPS, Barcelona, Spain) ; Nagels, Guy (National MS Center Melsbroek, Brussels, Belgium) ; Paquet, Claire (Research Memory Center Lariboisière Hospital University Paris Diderot INSERMU942, Paris, France) ; Parnetti, Lucilla (Section of Neurology, Centre for Memory Disturbances, Department of Medicine, University of Perugia, Perugia, Italy) ; Roks, Gerwin (Department of Neurology, St Elisabeth Ziekenhuis, Tilburg, The Netherlands) ; Rosa-Neto, Pedro (Departments of Psychiatry, McGill Centre for Studies in Aging, Douglas Hospital Research Center, McGill University, Montreal, Canada) ; Scheltens, Philip (Alzheimer center and Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands) ; Skårsgard, Constance (Department of Geriatrics, Kalmar County Hospital, Kalmar, Sweden) ; Stomrud, Erik (Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden) ; Tumani, Hayrettin (CSF Laboratory and Multiple Sclerosis Outpatient Unit, Department of Neurology, University of Ulm, Ulm, Germany) ; Visser, Pieter Jelle (Alzheimer Centre Limburg, School for Mental Health and Neuroscience, Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands) ; Wallin, Anders (Memory Clinic, Department of Neuropsychiatry, Sahlgrenska University Hospital, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden) ; Winblad, Bengt (Karolinska Institutet, Department of Neurobiology, Care Sciences and Society (NVS), Center for Alzheimer Research, Division for Neurogeriatrics, Huddinge, Sweden) ; Zetterberg, Henrik (UCL Institute of Neurology, Department of Molecular Neuroscience, London, United Kingdom) ; Duits, Flora (Alzheimer center and Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands) ; Teunissen, Charlotte E. (Neurochemistry Laboratory and Biobank, Department of Clinical Chemistry, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands) ; Universitat Autònoma de Barcelona
Cerebrospinal fluid collection by lumbar puncture (LP) is performed in the diagnostic workup of several neurological brain diseases. Reluctance to perform the procedure is among others due to a lack of standards and guidelines to minimize the risk of complications, such as post-LP headache or back pain. [...]
2017 - 10.1016/j.dadm.2017.04.007
Alzheimer's & dementia, Vol. 8 (may 2017) , p. 111-126  
8.
10 p, 566.6 KB Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome / Dekker, Alain D. (University of Antwerp) ; Fortea, Juan (Institut d'Investigació Biomèdica Sant Pau) ; Blesa, Rafael (Institut d'Investigació Biomèdica Sant Pau) ; De Deyn, Peter P. (Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium) ; Universitat Autònoma de Barcelona
Down syndrome (DS), present in nearly six million people, is associated with an extremely high risk to develop Alzheimer's disease (AD). Amyloid-β and tau pathology are omnipresent from age 40 years onward, but clinical symptoms do not appear in all DS individuals. [...]
2017 - 10.1016/j.dadm.2017.02.006
Alzheimer's & dementia, Vol. 8 (march 2017) , p. 1-10  
9.
9 p, 542.1 KB Validation of semaphorin 7A and ala-β-his-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis / Cantó, Ester (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Tintoré, Mar ; Villar, Luisa Maria (Hospital Ramón y Cajal. Departamento de Neurología) ; Borrás, Eva (Universitat Pompeu Fabra (UPF). Proteomics Unit) ; Álvarez-Cermeño, Jose Carlos (Hospital Ramón y Cajal. Departamento de Neurología) ; Chiva, Cristina (Universitat Pompeu Fabra) ; Sabidó, Eduard (Universitat Pompeu Fabra (UPF). Proteomics Unit) ; Rovira, Alex (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Comabella, Manuel (Hospital Universitari Vall d'Hebron. Unitat de Neuroimmunologia Clínica) ; Universitat Autònoma de Barcelona
In a previous proteomics study using pooled cerebrospinal fluid (CSF) samples, we proposed apolipoprotein AI, apolipoprotein AIV, vitronectin, plasminogen, semaphorin 7A, and ala-β-his-dipeptidase as candidate biomarkers associated with the conversion to clinically definite multiple sclerosis (CDMS) in patients with clinically isolated syndromes (CIS). [...]
2014 - 10.1186/s12974-014-0181-8
Journal of neuroinflammation, Vol. 11 (november 2014)  
10.
8 p, 172.8 KB Recaída neurológica en perros con linfoma tratados con quimioterapia: revisión de 13 casos / Martínez de Merlo, E. M. (Universidad Complutense de Madrid. Departamento de Medicina y Cirugía Animal) ; Portero, M. (Universidad Complutense de Madrid. Departamento de Medicina y Cirugía Animal) ; Costo, J. M. (Universidad Complutense de Madrid. Departamento de Medicina y Cirugía Animal) ; Arconada, L. (Universidad Complutense de Madrid. Departamento de Medicina y Cirugía Animal)
Se realiza un estudio retrospectivo de 13 casos de perros tratados con quimioterapia por linfoma que sufren recaída con afectación del sistema nervioso central o periférico, con el fin de describir los hallazgos encontrados y respuesta al tratamiento de los mismos. [...]
2011
Clínica veterinaria de pequeños animales, Vol. 31 Núm. 4 (2011)  

Research literature 1 records found  
1.
220 p, 3.9 MB Búsqueda de Biomarcadores asociados a la conversión a esclerosis múltiple en pacientes con síndromes clínicos aislados / Cantó Puig, Ester ; Comabella López, Manuel, dir. ; Montalbán Gairín, Xavier, dir. (Universitat Autònoma de Barcelona. Departament de Medicina) ; Jaraquemada, Dolores, tut. (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia
Aproximadamente el 85% de los pacientes con esclerosis múltiple (EM) inician la enfermedad con un síndrome clínico aislado (CIS), pero se ha descrito que entre un 30 y un 85% de los pacientes que presentan un CIS finalmente desarrollan EM clínicamente definida (EMCD). [...]
In about 85% of patients with multiple sclerosis (MS) the disease starts with a clinically isolated syndrome (CIS), but only 30 to 85% of patients with CIS finally develop clinically definite MS (CDMS). [...]

[Barcelona] : Universitat Autònoma de Barcelona, 2015  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.